pirarubicin and Nervous-System-Diseases

pirarubicin has been researched along with Nervous-System-Diseases* in 1 studies

Other Studies

1 other study(ies) available for pirarubicin and Nervous-System-Diseases

Article	Year
[Glutathione chemoprotection therapy against CDDP-induced neurotoxicity in patients with invasive bladder cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11 We studied the efficacy of glutathione in the prevention of CDDP-induced neurotoxicity. Nine patients with muscle-invasive bladder cancer were treated with intra-arterial THP and CDDP chemotherapy plus radiotherapy. Glutathione was given at a dose of 1,500 mg/m2 before CDDP administration and at a dose of 600 mg/body on days 2 to 4. The CR rate of 9 patients was 89%, and 2 of the 9 patients developed grade 1 neurotoxicity. These patients were then compared with 15 patients treated with the same regiment but without glutathione. The two groups did not differ in CR rate (89% vs 87%), but the incidence of neurotoxicity of patients with glutathione was significantly lower than that of patients without glutathione (22% vs 73%). Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Glutathione; Humans; Male; Middle Aged; Nervous System Diseases; Sensation; Urinary Bladder Neoplasms	1996

Article

Year

[Glutathione chemoprotection therapy against CDDP-induced neurotoxicity in patients with invasive bladder cancer].

Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

We studied the efficacy of glutathione in the prevention of CDDP-induced neurotoxicity. Nine patients with muscle-invasive bladder cancer were treated with intra-arterial THP and CDDP chemotherapy plus radiotherapy. Glutathione was given at a dose of 1,500 mg/m2 before CDDP administration and at a dose of 600 mg/body on days 2 to 4. The CR rate of 9 patients was 89%, and 2 of the 9 patients developed grade 1 neurotoxicity. These patients were then compared with 15 patients treated with the same regiment but without glutathione. The two groups did not differ in CR rate (89% vs 87%), but the incidence of neurotoxicity of patients with glutathione was significantly lower than that of patients without glutathione (22% vs 73%).

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Glutathione; Humans; Male; Middle Aged; Nervous System Diseases; Sensation; Urinary Bladder Neoplasms

1996